FDA Approves ORKAMBI — Vertex Pharmaceuticals Incorporated

# FDA Approves Vertex Pharmaceuticals' ORKAMBI for Cystic Fibrosis Treatment Vertex Pharmaceuticals Incorporated announced FDA approval of ORKAMBI (lumacaftor and ivacaftor) on August 7, 2018, expanding the company's cystic fibrosis portfolio and strengthening its market position in orphan diseases. The oral combination therapy is expected to drive revenue growth and reinforce Vertex's dominance in the CF treatment market, where the company already commands significant market share with complementary therapies.